enliven therapeutics focuses on the discovery and development of next generation small molecule treatments for cancer. we are backed by top-tier life science venture funds. we seek experienced and passionate drug hunters to join our team as we grow our r&d organization in boulder, co.
Company profile
Ticker
ELVN
Exchange
Website
CEO
Rahul D. Ballal
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
IMARA Inc.
SEC CIK
Corporate docs
Subsidiaries
Enliven Inc. • IMARA Security Corporation ...
IRS number
811523849
ELVN stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
S-3
Shelf registration
18 Apr 24
PRE 14A
Preliminary proxy
15 Apr 24
8-K
Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
11 Apr 24
8-K
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors
9 Apr 24
D
$90.00 mm in equity / options / securities to be acquired, sold $90.00 mm, 20 investors
3 Apr 24
8-K
Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates
19 Mar 24
S-8
Registration of securities for employees
14 Mar 24
Transcripts
ELVN
Earnings call transcript
2021 Q4
15 Mar 22
ELVN
Earnings call transcript
2021 Q3
9 Nov 21
ELVN
Earnings call transcript
2021 Q2
8 Aug 21
ELVN
Earnings call transcript
2021 Q1
11 May 21
ELVN
Earnings call transcript
2020 Q4
5 Mar 21
ELVN
Earnings call transcript
2020 Q3
7 Nov 20
ELVN
Earnings call transcript
2020 Q2
14 Aug 20
Latest ownership filings
SC 13D/A
5AM Ventures VI, L.P.
15 Apr 24
4
Anish Patel
15 Apr 24
4
Joseph P Lyssikatos
15 Apr 24
4
Samuel Kintz
15 Apr 24
4
Benjamin Hohl
15 Apr 24
4
Richard A. Heyman
15 Apr 24
4
Helen Louise Collins
15 Apr 24
4
Rahul D. Ballal
12 Apr 24
144
Notice of proposed sale of securities
11 Apr 24
144
Notice of proposed sale of securities
11 Apr 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 73.90 mm | 73.90 mm | 73.90 mm | 73.90 mm | 73.90 mm | 73.90 mm |
Cash burn (monthly) | 17.29 mm | 1.03 mm | 8.08 mm | 2.62 mm | 5.30 mm | 5.04 mm |
Cash used (since last report) | 119.52 mm | 7.09 mm | 55.87 mm | 18.11 mm | 36.62 mm | 34.81 mm |
Cash remaining | -45.62 mm | 66.81 mm | 18.03 mm | 55.79 mm | 37.28 mm | 39.09 mm |
Runway (months of cash) | -2.6 | 65.1 | 2.2 | 21.3 | 7.0 | 7.8 |
Institutional ownership, Q3 2023
97.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 64 |
Opened positions | 8 |
Closed positions | 8 |
Increased positions | 22 |
Reduced positions | 23 |
13F shares | Current |
---|---|
Total value | 533.40 bn |
Total shares | 45.76 mm |
Total puts | 0.00 |
Total calls | 11.08 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Orbimed Advisors | 9.00 mm | $122.92 bn |
5AM Venture Management | 5.16 mm | $70.50 bn |
5AM Ventures VI | 4.47 mm | $76.05 mm |
FMR | 3.68 mm | $50.22 bn |
VR Adviser | 2.95 mm | $40.36 bn |
Commodore Capital | 2.90 mm | $39.64 bn |
Citadel Advisors | 2.35 mm | $32.12 bn |
Venrock Healthcare Capital Partners III | 2.21 mm | $48.93 mm |
Fairmount Funds Management | 2.13 mm | $29.11 bn |
Ra Capital Management | 2.12 mm | $28.99 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Apr 24 | Heyman Richard A. | Common Stock | Sell | Dispose S | No | Yes | 20.6773 | 80 | 1.65 k | 137,155 |
15 Apr 24 | Heyman Richard A. | Common Stock | Sell | Dispose S | No | Yes | 19.9403 | 1,190 | 23.73 k | 137,235 |
11 Apr 24 | Collins Helen Louise | Common Stock | Sell | Dispose S | No | Yes | 25.0739 | 20,000 | 501.48 k | 0 |
11 Apr 24 | Collins Helen Louise | Common Stock | Option exercise | Acquire M | No | Yes | 2.48 | 20,000 | 49.60 k | 20,000 |
11 Apr 24 | Collins Helen Louise | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 2.48 | 20,000 | 49.60 k | 267,084 |
11 Apr 24 | Heyman Richard A. | Common Stock | Sell | Dispose S | Yes | Yes | 25 | 649 | 16.23 k | 28,567 |
11 Apr 24 | Heyman Richard A. | Common Stock | Sell | Dispose S | No | Yes | 25.0306 | 5,045 | 126.28 k | 138.425 |
11 Apr 24 | Samuel Kintz | Common Stock | Sell | Dispose S | No | Yes | 25.0414 | 47,709 | 1.19 mm | 0 |
11 Apr 24 | Samuel Kintz | Common Stock | Option exercise | Acquire M | No | Yes | 1.12 | 47,709 | 53.43 k | 47,709 |
11 Apr 24 | Samuel Kintz | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 1.12 | 47,709 | 53.43 k | 212,841 |
News
Enliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Program
11 Apr 24
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
11 Apr 24
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
11 Apr 24
Enliven Therapeutics Announces Proof Of Concept Data From Phase 1 Clinical Trial Of ELVN-001 In Chronic Myeloid Leukemia
11 Apr 24
Enliven Therapeutics Well-Positioned, With Conservative Trading Levels-Analyst Says
9 Apr 24